Home › Funds › Rosalind Advisors, Inc. › SVRA
Rosalind Advisors, Inc. position in SVRA
Savara Inc · Health Care
Rosalind Advisors, Inc. reported holding 3,178,121 shares of SVRA (Savara Inc) in its Q2 2026 13F filing — a position valued at US$19.6M, representing 7.28% of its reported portfolio and ranking #4 among its reported holdings. Rosalind Advisors, Inc. has disclosed SVRA holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Rosalind Advisors, Inc.'s SVRA position evolved
Rosalind Advisors, Inc. first disclosed a stake in SVRA in Q4 2024 at 2,654,944 shares (US$8.2M). The position peaked in Q4 2025 at 3,403,721 shares, worth US$20.5M. Across 7 filings, Rosalind Advisors, Inc. increased the stake 1 time(s), trimmed it 3 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 3,178,121 shares valued at US$19.6M — a reduction of -25,600 shares quarter over quarter.. Notable position changes include a 51% increase in Q3 2025 (shares rose 69% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 2.65M | $8.15M | New |
| Q1 2025 | 2.65M | $7.35M | Hold |
| Q2 2025 | 2.65M | $6.05M | Hold |
| Q3 2025 | 4.00M | $14.28M | Add |
| Q4 2025 | 3.40M | $20.52M | Reduce |
| Q1 2026 | 3.20M | $17.49M | Reduce |
| Q2 2026 | 3.18M | $19.58M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SVRA and 13F data
SVRA (Savara Inc) is a Health Care company. 44 other funds we track also report a position in SVRA — the largest reported positions include NEA Management Company, LLC (US$150.7M), Bain Capital Life Sciences Investors, LLC (US$108.4M), Venrock Adviser, LLC (US$90.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SVRA
- NEA Management Company, LLC 24.47M sh · $150.74M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 17.60M sh · $108.42M · Q2 2026
- Venrock Adviser, LLC 14.75M sh · $90.84M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 13.57M sh · $83.59M · Q2 2026
- TCG Crossover Management, LLC 12.36M sh · $76.15M · Q2 2026
- Frazier Life Sciences Management, L.P. 9.72M sh · $59.88M · Q2 2026
- Nantahala Capital Management, LLC 6.98M sh · $42.98M · Q2 2026
- Spruce Street Capital LP 3.45M sh · $21.27M · Q2 2026
- Vestal Point Capital, LP 2.72M sh · $16.76M · Q2 2026
- Affinity Asset Advisors, LLC 2.51M sh · $15.47M · Q2 2026
- NAN FUNG TRINITY (HK) Ltd 1.84M sh · $11.35M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 1.36M sh · $8.35M · Q2 2026
More on Rosalind Advisors, Inc.
FAQ
How long has Rosalind Advisors, Inc. held SVRA?
Rosalind Advisors, Inc. has disclosed SVRA holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
What is Rosalind Advisors, Inc.'s current position in SVRA?
As of Q2 2026, Rosalind Advisors, Inc. holds 3.18M shares of SVRA (Savara Inc), valued at $19.58M, representing 7.28% of its reported portfolio and ranking #4.
Has Rosalind Advisors, Inc. been buying or selling SVRA?
In the latest 13F filing (Q2 2026), Rosalind Advisors, Inc. reduced its position in SVRA. The position peaked in Q4 2025 at 3.40M shares.
Which other funds hold SVRA?
Other major institutional holders of SVRA include NEA Management Company, LLC, Bain Capital Life Sciences Investors, LLC, Venrock Adviser, LLC, among 44 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.